Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Holdings Lifted by Commodore Capital LP

Commodore Capital LP lifted its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGXGet Rating) by 61.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 805,573 shares of the company’s stock after buying an additional 307,494 shares during the period. Protagonist Therapeutics makes up 6.4% of Commodore Capital LP’s investment portfolio, making the stock its 6th largest holding. Commodore Capital LP owned about 1.69% of Protagonist Therapeutics worth $27,551,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Point72 Asset Management L.P. grew its position in Protagonist Therapeutics by 279.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 4,387,300 shares of the company’s stock worth $77,743,000 after purchasing an additional 3,232,100 shares during the last quarter. Johnson & Johnson purchased a new position in Protagonist Therapeutics during the 3rd quarter worth $43,400,000. EcoR1 Capital LLC purchased a new position in Protagonist Therapeutics during the 3rd quarter worth $25,584,000. State Street Corp grew its position in Protagonist Therapeutics by 27.7% during the 4th quarter. State Street Corp now owns 2,571,570 shares of the company’s stock worth $87,948,000 after purchasing an additional 557,591 shares during the last quarter. Finally, Voloridge Investment Management LLC grew its position in Protagonist Therapeutics by 8,357.6% during the 3rd quarter. Voloridge Investment Management LLC now owns 550,083 shares of the company’s stock worth $9,747,000 after purchasing an additional 543,579 shares during the last quarter.

Shares of NASDAQ PTGX opened at $9.20 on Friday. The company has a 50-day simple moving average of $14.56 and a 200-day simple moving average of $24.64. Protagonist Therapeutics, Inc. has a 12 month low of $7.39 and a 12 month high of $50.54.

PTGX has been the topic of several research reports. Piper Sandler lowered their price objective on shares of Protagonist Therapeutics from $60.00 to $35.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 17th. Zacks Investment Research cut shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 11th. StockNews.com cut shares of Protagonist Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 20th. Finally, BTIG Research reduced their target price on shares of Protagonist Therapeutics from $55.00 to $45.00 in a research note on Tuesday, April 26th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, Protagonist Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $46.11.

Protagonist Therapeutics Profile (Get Rating)

Protagonist Therapeutics, Inc, a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications.

See Also

Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGXGet Rating).

Institutional Ownership by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.